Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0003613090

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets


share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 01:59pm CET

Moberg Pharma's Nomination Committee ahead of the 2018 Annual General Meeting comprises:

  • Thomas Eklund, Chairman of the Board
  • Gillis Cullin, appointed by Östersjöstiftelsen
  • Fredrik Persson, appointed by Zimbrine Holding
  • Anders Rodebjer, appointed by Wolco Invest

Together, the Nomination Committee represents 25.3 percent of the shares in Moberg Pharma as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors' fees and the election of auditors.

The 2018 Annual General Meeting will be held in Stockholm on May 15.

Shareholders wishing to submit proposals to Moberg Pharma's Nomination Committee can do so by e-mail to [email protected] by 31 December 2017.

About this information
This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on November 10th, 2017.

For additional information, please contact:
Peter Wolpert, CEO, Phone: +1 908 432 22 03 (US), +46 707 35 71 35 (SE), E-mail: [email protected]
Anna Ljung, CFO, Phone: +46 707 66 60 30, E-mail: [email protected]

About Moberg Pharma, www.mobergpharma.comMoberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company's portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, New Skin®, Dermoplast®and Domeboro®. Kerasal Nail®(Emtrix®, Zanmira®or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two assets in late-stage clinical development, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Moberg Pharma AB published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 12:58:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MOBERG PHARMA AB (PUBL)
01/16 MOBERG PHARMA PUBL : Receives Favorable Outcome From NAD - Main Competitor to Di..
01/15 MOBERG PHARMA PUBL : receives favorable outcome from NAD – main competitor..
01/15 MOBERG PHARMA PUBL : receives favorable outcome from NAD - main competitor to di..
2017 MOBERG PHARMA PUBL : reorganizes its commercial operations
2017 MOBERG PHARMA PUBL : Acquires Assets from IM HealthScience (Fiber Choice)
2017 MOBERG PHARMA PUBL : replaces CRO in Phase 3 studies for MOB-015
2017 MOBERG PHARMA AB : interim report January - September 2017
2017 MOBERG PHARMA PUBL : Nomination committee appointed
2017 MOBERG PHARMA PUBL : Nomination committee appointed
2017MOBERG PHARMA AB (PUBL) : quaterly earnings release
More news
News from SeekingAlpha
2017 Moberg Pharma (MBGRF) Presents At Pareto Securities' 8th Annual Health Care S..
Financials ( SEK)
Sales 2017 434 M
EBIT 2017 43,4 M
Net income 2017 2,20 M
Debt 2017 472 M
Yield 2017 -
P/E ratio 2017 124,35
P/E ratio 2018
EV / Sales 2017 2,24x
EV / Sales 2018 2,46x
Capitalization 499 M
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MOB | SE0003613090 | 4-Traders
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus
Number of Analysts 2
Average target price 56,9  SEK
Spread / Average Target 99%
EPS Revisions
Peter Gunnar Maurits Wolpert Chief Executive Officer
Thomas Lennart Eklund Chairman
Anna Ljung Chief Financial Officer
Kjell Rensfeldt Chief Medical Officer, VP-Research & Development
Torbjörn Mattias Koivisto Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132